Morning Editorial Report: Hillary Attacks a Drug Maker

The Wall Street Journal

Morning Editorial Report

Hillary Attacks a Drug Maker

By JAMES FREEMAN

Hillary Clinton is attacking drug maker Mylan for what she calls the “outrageous” cost of its EpiPen treatment for anaphylaxis. A Journal editorial notes that Mylan’s monopoly was “created by the same government that Mrs. Clinton wants to hand far more power over drugs.” Potential competitors to EpiPen haven’t been able to win the approval of the Food and Drug Administration.

Former Federal Reserve Governor Kevin Warsh says the Fed is “vulnerable” politically and in need of broad reform. Among its problems, the central bank “appears in thrall to financial markets, and financial markets are in thrall to the Fed.” Mr. Warsh notes a “simple, troubling fact: From the beginning of 2008 to the present, more than half of the increase in the value of the S&P 500 occurred on the day of Federal Open Market Committee decisions.”

Donald Trump has changed, writes Fred Barnes. “Mr. Trump leashed himself to the teleprompter. He apologized for causing pain to those he had attacked,” and he has lately been making efforts to appeal to minority voters. Mr. Barnes thinks the GOP candidate can win if he continues “to make Mrs. Clinton into issue No. 1 and force her to play defense.”

Karl Rove argues there’s no defense for the Clinton Foundation and it should be closed immediately. The outfit “received many millions of dollars from foreign governments and nationals while Mrs. Clinton was secretary of state, including via a Canadian front group set up to shield donors’ identities. This despite Mrs. Clinton’s promise at her January 2009 confirmation to provide ‘the transparency and disclosure that is needed’ and ‘address even the appearance of conflict,’” writes Mr. Rove.

Read today's full column »